Takara Bio Inc. revised consolidated earnings guidance for the fiscal year ending March 31, 2023. The company expects net sales to be JPY 77,800 million, Operating profit to be JPY 20,000 million, profit attributable to owners of parent to be JPY 14,500 million or JPY 120.42 per basic share against previously expected net sales to be JPY 77,800 million, Operating profit to be JPY 19,000 million, profit attributable to owners of parent to be JPY 13,800 million or JPY 114.60 per basic share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,088 JPY | +2.64% | +7.51% | -13.10% |
May. 10 | Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024 | CI |
Mar. 18 | Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.10% | 816M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+50.18% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- 4974 Stock
- News Takara Bio Inc.
- Takara Bio Inc. Revised Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023